Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies

Basis for an Expanded National Donor Serosurveillance Program

Stone, Mars
Di Germanio, Clara
Wright, David J
Sulaeman, Hasan
Dave, Honey
Fink, Rebecca V
Notari, Edward P
Green, Valerie
Strauss, Donna
Kessler, Debbie
Destree, Mark
Saa, Paula
Williamson, Phillip C
Simmons, Graham
Stramer, Susan L
Opsomer, Jean
Jones, Jefferson M
Kleinman, Steven
Busch, Michael P
Cassetti, C
Gerber, S
Patton, M
Havers, F
Basavaraju, S
Williams, A E
Anderson, S
Haynes, J
McCain, L
Hui, A
Samuels, C
Tanner, H
Kaidarova, Z
B, M P
Norris, P J
S, M
Mathew, S M
Stramer, S
Kessler, D
Konkle, B A
Custer, B
Ness, P M
Kleinman, S H
Josephson, C D
Glynn, S A
Malkin, K

Vitalant Research Institute, San Francisco, California, USA
Department of Laboratory Medicine, University of California, San Francisco, California, USA
Westat, Rockville, Maryland, USA
American Red Cross, Gaithersburg, Maryland, USA
Creative Testing Solutions, Tempe, Arizona, USA
New York Blood Center, New York, New York, USA
Blood Works Northwest, Seattle, Washington, USA
Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA
University of British Columbia, Victoria, British Columbia, Canada

Correspondence: M. P. Busch, Vitalant Research Institute, 270 Masonic Ave, San Francisco, CA 94118 ([email protected]).

Received April 24, 2021

Revised July 31, 2021

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Clinical Infectious Diseases 74(5):p 871-881, March 01, 2022. | DOI: 10.1093/cid/ciab537